These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26684327)

  • 1. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
    Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
    BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
    Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
    Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece.
    Kourlaba G; Gourzoulidis G; Andrikopoulos G; Tsioufis K; Beletsi A; Maniadakis N
    BMC Health Serv Res; 2016 Sep; 16(1):520. PubMed ID: 27678370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
    Kohn CG; Parker MW; Limone BL; Coleman CI
    Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
    Coleman CI; Freemantle N; Kohn CG
    BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
    Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
    BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
    Nguyen E; Coleman CI; Kohn CG; Weeda ER
    Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
    Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
    Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
    Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
    Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
    Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
    Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.
    Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S
    J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
    Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
    Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
    Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
    Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
    Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
    Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.